Two-year data confirm vision gain, fluid reduction with Beovu treatment in DME
Patients with diabetic macular edema experienced visual acuity gains and reduced central subfield thickness after 2 years of treatment with Beovu, according to a press release from Novartis.
Week 100 results of the phase 3 KESTREL study confirmed previous 1-year results and showed Beovu (brolucizumab) was beneficial and safe in patients with visual impairment due to DME.
The study compared the safety and efficacy of brolucizumab and Eylea (aflibercept, Regeneron) in patients with DME. Patients in the brolucizumab arm were treated every 6 weeks for a total of five doses, while patients in the aflibercept arm were treated every 4 weeks for a total of five doses. After the loading phase, patients who received brolucizumab were treated every 12 weeks, moving to dosing every 8 weeks if they demonstrated disease activity.
Treatment was maintained on 12-week dosing intervals for more than 40% of patients in the brolucizumab arm, and 70% of patients who completed the first 12-week cycle after the loading phase remained on 12-week dosing through 2 years of treatment.
In addition to improved visual acuity and reduced central subfield thickness, fewer patients treated with brolucizumab had intraocular fluid or subretinal fluid compared with patients in the aflibercept arm.
Read more about